Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Cerilliant
Federal Trade Commission
Merck
Mallinckrodt
Fish and Richardson
Farmers Insurance
Fuji
Daiichi Sankyo

Generated: November 15, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 208684

« Back to Dashboard

NDA 208684 describes EMFLAZA, which is a drug marketed by Ptc Therap and is included in two NDAs. It is available from two suppliers. Additional details are available on the EMFLAZA profile page.

The generic ingredient in EMFLAZA is deflazacort. There are three drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the deflazacort profile page.
Summary for 208684
Tradename:EMFLAZA
Applicant:Ptc Therap
Ingredient:deflazacort
Patents:0
Generic Entry Opportunity Date for 208684
Generic Entry Date for 208684*:
Constraining patent/regulatory exclusivity:
TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY IN PATIENTS 5 YEARS OF AGE AND OLDER
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for NDA: 208684
Suppliers and Packaging for NDA: 208684
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
EMFLAZA deflazacort TABLET;ORAL 208684 NDA Marathon Pharmaceuticals, LLC 42998-501 42998-501-01 100 TABLET in 1 BOTTLE (42998-501-01)
EMFLAZA deflazacort TABLET;ORAL 208684 NDA Marathon Pharmaceuticals, LLC 42998-502 42998-502-03 30 TABLET in 1 BOTTLE (42998-502-03)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength6MG
Approval Date:Feb 9, 2017TE:RLD:Yes
Regulatory Exclusivity Expiration:Feb 9, 2022
Regulatory Exclusivity Use:NEW CHEMICAL ENTITY
Regulatory Exclusivity Expiration:Feb 9, 2024
Regulatory Exclusivity Use:TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY IN PATIENTS 5 YEARS OF AGE AND OLDER

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength18MG
Approval Date:Feb 9, 2017TE:RLD:Yes
Regulatory Exclusivity Expiration:Feb 9, 2022
Regulatory Exclusivity Use:NEW CHEMICAL ENTITY

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Dow
McKesson
Moodys
AstraZeneca
Express Scripts
Queensland Health
Accenture
UBS
Farmers Insurance

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.